Abstract
Treatment with doxorubicin (dox) and emodin, separately and together, under normoxic and hypoxia-like conditions induced by CoCl2, led to greater intracellular compound accumulation over 10 h post-addition in the presence of CoCl2 in lung adenocarcinoma (A549) and colorectal carcinoma (HCT-15) cell lines. Confocal microscopy revealed that emodin, by itself, showed high cytosolic distribution in both cell lines, at 40 min post-addition but had entered the nuclei by 2 h, while dox entered the nuclei by 40 min. Both compounds modulated the expression of the efflux transporters (PgP, ABCG2, or MRP1-4) and the endocytic receptor, low-density lipoprotein receptor-related protein 1 (LRP1), to different extents under the study conditions. Efflux transporter upregulation was linked to lower intracellular compound levels due to greater efflux. Increased dox accumulation was accompanied by unaltered expression or upregulation of LRP1 in A549 cells. In both cell lines, increased accumulation of dox and emodin was observed whenever LRP1 and the efflux transporters known to transport dox and emodin were all up- or downregulated concomitantly. Increased growth inhibition was linked to co-treatment with dox and emodin and with increased ligand accumulation. The results presented in this study raise the hypothesis that higher production of LRP1 protein may be associated with higher endocytosis of upregulated transporter proteins at the cell surface, and hence, increased dox and emodin accumulation and growth inhibition. If so, elevation of LRP1 expression may be a useful target for interventions to promote the efficacy of these and other anticancer drugs.
References
Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS (2014) Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840:615–625
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6:133–146
Walker J, Martin C, Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer Oxf Engl 40:594–605
Argov M, Kashi R, Peer D, Margalit R (2009) Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 274:118–125
Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512
Torky A-RW, Stehfest E, Viehweger K, Taege C, Foth H (2005) Immuno-histochemical detection of MRPs in human lung cells in culture. Toxicology 207:437–450
van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS (2005) ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6:59
Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347–357
Thews O, Gassner B, Kelleher DK, Gekle M (2008) Activity of drug efflux transporters in tumor cells under hypoxic conditions. Adv Exp Med Biol 614:157–164
Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS (1988) Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48:6365–6370
Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910
Folmer Y, Schneider M, Blum HE, Hafkemeyer P (2007) Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther 14:875–884
Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res Off J Am Assoc Cancer Res 7:1798–1804
Dandekar DS, Lokeshwar BL (2005) Emodin synergistically enhances docetaxel induced apoptosis in androgen-responsive prostate cancer cells. Cancer Res 65:723–723
Huang X, Wang J, Huang C, Chen Y, Shi G, Hu Q, Yi J (2008) Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7:468–475
Wang W, Sun Y, Huang X, He M, Chen Y, Shi G, Li H, Yi J, Wang J (2010) Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79:1134–1140
Yu C-X, Zhang X-Q, Kang L-D, Zhang P-J, Chen W-W, Liu W-W, Liu Q-W, Zhang J-Y (2008) Emodin induces apoptosis in human prostate cancer cell LNCaP. Asian J Androl 10:625–634
Masaldan S, Iyer VV (2014) Exploration of effects of emodin in selected cancer cell lines: enhanced growth inhibition by ascorbic acid and regulation of LRP1 and AR under hypoxia-like conditions. J Appl Toxicol JAT 34:95–104
Kuo T-C, Yang J-S, Lin M-W, Hsu S-C, Lin J-J, Lin H-J, Hsia T-C, Liao C-L, Yang M-D, Fan M-J et al (2009) Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330:736–744
Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X (2016) Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer 16:578
Richard V, Nair MG, Kumar TRS, Pillai MR (2013) Side population cells as prototype of chemoresistant, tumor-initiating cells. BioMed Res Int 2013:e517237
Huang Q, Shen H-M, Shui G, Wenk MR, Ong C-N (2006) Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res 66:5807–5815
Kawata K, Kubota S, Eguchi T, Aoyama E, Moritani NH, Kondo S, Nishida T, Takigawa M (2012) Role of LRP1 in transport of CCN2 protein in chondrocytes. J Cell Sci 125:2965–2972
Campana WM, Li X, Dragojlovic N, Janes J, Gaultier A, Gonias SL (2006) The low-density lipoprotein receptor-related protein is a pro-survival receptor in Schwann cells: possible implications in peripheral nerve injury. J Neurosci Off J Soc Neurosci 26:11197–11207
Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ et al (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883–887
Montel V, Gaultier A, Lester RD, Campana WM, Gonias SL (2007) The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development. Cancer Res 67:9817–9824
Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschild C, Strickland DK (2005) Platelet-derived growth factor receptor-β (PDGFR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP) evidence for co-receptor function. J Biol Chem 280:27872–27878
Goldberg MA, Schneider TJ (1994) Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269:4355–4359
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823
Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res Off J Am Assoc Cancer Res 6:1949–1957
Al-Nuri MA, Za’tar NA, Abu-Eid MA, Hannoun MA, Al-Jondi WJ, Hussein AI, Ali-Shtayeh MS (1996) Emodin, a naturally occuring anthraquinone: its isolation and spectrophotometric determination in rumex cyprius plant. Spectrosc Lett 29:1539–1543
Barenolz Y, Haran G (1993). Method of amphiphatic drug loading in liposomes by pH gradient (Google Patents). http://www.google.co.in/patents/US5192549
Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422–427
Ying Y, Qingwu L, Mingming X, Zhenju S, Chaoyang T, Zhengang T (2017) Emodin: one main ingredient of Shufeng Jiedu capsule reverses chemoresistance of lung cancer cells through inhibition of EMT. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 42:1063–1072
Li X, Dong Y, Wang W, Wang H, Chen Y, Shi G, Yi J, Wang J (2013) Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma. Stem Cells Dev 22:554–566
Wei W-T, Lin S-Z, Liu D-L, Wang Z-H (2013) The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep 30:2555–2562
Drug combinations to overcome treatment resistance. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/research/drug-combo-resistance. Accessed 15 Feb 2018
Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8:38022–38043
Acton QA (2012) ATP-binding cassette transporters: advances in research and application. 2011 Edition: ScholarlyBrief (ScholarlyEditions). https://books.google.co.in/books?id=8ExP72uUt-kC
Acknowledgements
The authors thank Dr. K.G. Thirumurugaan (Translational Research Platform for Veterinary Biologicals, Tamil Nadu Veterinary and Animal Sciences University) for his support in confocal microscopy. We are also grateful to Ms. Kavitha Murugan for her help with the revision of figures. This study and YP (as Junior Research Fellow) were supported financially through SB/YS/LS-138/2013 from Science Engineering and Research Board (SERB), Government of India.
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: VI; performed the experiments: JK (GI, qPCR), YP (accumulation, qPCR); analyzed the data: VI, JK, YP; wrote the paper: VI.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest in this study.
Rights and permissions
About this article
Cite this article
Iyer, V.V., Priya, P.Y. & Kangeyavelu, J. Effects of increased accumulation of doxorubicin due to emodin on efflux transporter and LRP1 expression in lung adenocarcinoma and colorectal carcinoma cells. Mol Cell Biochem 449, 91–104 (2018). https://doi.org/10.1007/s11010-018-3346-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-018-3346-4